Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BLPH | Stock Options (Right to Buy) | Award | $0 | -14.6K | -50% | $0.00 | 14.6K | Jun 7, 2023 | Common Stock | 14.6K | $0.83 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | This option was approved by the Compensation Committee of the Board of Directors of Bellerophon Therapeutics, Inc., on February 10, 2023, contingent upon stockholder approval of an amendment to the Company's 2015 Equity Incentive Plan under which the options were granted, which was approved by stockholders on June 7, 2023. |
F2 | This option vests in full on June 7, 2024. |